The nonprofit European Foundation for Clinical Nanomedicine will have after two virtual summits in 2020 & 2022 its 14th Summit as a hybrid event with personal attendance and live stream. CLINAM 14 /2023 will be the unique traditional platform with a scientific programme that will elucidate the state of the art of nanomedicine in production, development and the clinic for prevention, diagnosis and therapy. Since the development of mRNA vaccines based on lipid nanoparticles, nanomedicine has received huge awareness and has matured to a boosting field with highest recognition. This is the right moment to review the development of the technology as well as looking at the products and their use in clinical medicine at patient’s bed. The achievement of the revolutionary protective wall against COVID ‐19 by mRNA vaccines predicts a profound acceleration of innovative drug development to the benefit of patients. However, not for all humankind: How can we enable and improve health care in countries where therapy until today is unaffordable or absent? For this, delivery of drugs by different nanoparticles shall be an important issue. All stakeholders in the field, including many high‐ ranking scientists, Nobel Laureates and leading managers and regulatory authorities from all continents exploit the CLINAM‐summit since 15 years for new projects and making bonds for cooperation. All speakers contribute to an excellent scientific outlook. For 2023, CLINAM addressed three outstanding organizers of renowned conferences and invited them to participate with a session within the CLINAM‐Summit. The different skills of the parties will give a unique interdisciplinary perspective on nanomedicine and related fields in Europe and on the International level. The international Regulatory Authorities shall have their IPRP Meeting during the Summit.
Format of the Meeting
The Summit will take place on the Novartis Campus in Basel, which is since last year open to the public. The summit shall have on one day only plenary sessions and will take place in the auditorium, which is located in the impressive building designed by the architect Frank Gehry. The exhibition, poster presentations and lunches will be in the Foyer of the halls. The CLINAM Team will organize the meeting with as few as possible hurdles for the participants and is grateful for the support that Novartis gives by making the halls available to CLINAM.
Target Audience
The faculty includes pioneers and opinion leaders in medicine, nanoscience, and targeted medicine, physicians and scientists with a background in pharmacology, biology, physics, chemistry, biophysics, medicine, materials science, and engineering. Industry members find contacts for cooperation, get insight into the novel concepts 4 and meet keen investigating startups, interested in working together. Developers from the pharmaceutical industry present their recent findings and research. The meeting is a particularly useful source of knowledge for the targeted medicine and delivery community. The conference is also of interest to members of the regulatory authorities as well as policymakers, all experts from industry in the field of life sciences, developers of new tools and materials for nanomedicine, and all those investigating the potential of emerging technologies in the field of healthcare and their combinations. Experts from venture companies can acquire knowledge on existing and upcoming developments and novel products in the establishing field of nanomedicine and knowledge‐based medicine. Government authorities can profit from the international regulator’s sessions. CLINAM is the worldwide melting pot for experts and a high‐level communication platform where you meet those striving for nanomedical goals.
